ADAR1 Capital Management »

Taysha Gene Therapies shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Taysha Gene Therapies (TSHA) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Taysha Gene Therapies

Tip: Access up to 7 years of quarterly data

All positions including Taysha Gene Therapies held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Taysha Gene Therapies by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $125k 44k 2.87
2023-12-31 $370k 209k 1.77

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Taysha Gene Therapies

BlackRock
BlackRock
RA Capital Management
VR Adviser
Morgan Stanley
Vanguard Group
Siren
Octagon Capital Advisors
Baker Bros. Advisors
Geode Capital Management
State Street Corporation
Jpmorgan Chase & Co
Citadel Advisors
Deutsche Bank Aktiengesellschaft
Northern Trust

View all funds holding Taysha Gene Therapies